Catalent (NYSE:CTLT) is set to announce its earnings results before the market opens on Tuesday, November 6th. Analysts expect the company to announce earnings of $0.24 per share for the quarter.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.06. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The company had revenue of $685.30 million during the quarter, compared to analysts’ expectations of $690.69 million. During the same period in the prior year, the company posted $0.65 earnings per share. Catalent’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, analysts expect Catalent to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
CTLT opened at $42.05 on Friday. Catalent has a twelve month low of $36.73 and a twelve month high of $47.87. The company has a quick ratio of 1.79, a current ratio of 2.15 and a debt-to-equity ratio of 2.44. The firm has a market cap of $6.11 billion, a PE ratio of 26.45, a PEG ratio of 2.50 and a beta of 1.45.
Several equities research analysts have recently weighed in on CTLT shares. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research report on Monday, July 9th. JPMorgan Chase & Co. increased their price objective on shares of Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. Finally, UBS Group began coverage on shares of Catalent in a report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target for the company. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Catalent has a consensus rating of “Buy” and a consensus target price of $49.33.
In other Catalent news, insider John R. Chiminski sold 130,545 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $45.32, for a total value of $5,916,299.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Lance Miyamoto sold 6,525 shares of the firm’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The disclosure for this sale can be found here. Insiders sold 184,335 shares of company stock valued at $8,161,727 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: How can you know how many shares are floating?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.